Home Apoptosis RIP kinase inhibitor HS-1371 For research use only.

HS-1371

HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro.

HS-1371 Chemical Structure

HS-1371 Chemical Structure

CAS No. 2158197-70-5

Purity & Quality Control

Batch: S877501 DMSO]13 mg/mL]false]Ethanol]4 mg/mL]false]Water]Insoluble]false Purity: 98.11%
98.11

HS-1371 Related Products

Biological Activity

Description HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro.
Targets
RIP3 kinase [1]
20.8 nM
In vitro
In vitro

HS-1371 shows an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. It displays a complete inhibitory effect on TNF-induced necroptosis signaling, showing no phosphorylation of RIP3 and MLKL in HT-29 cells. Inhibition of RIP3 kinase activity by HS-1371 blocks necrosome complex formation, showing disruption of MLKL recruitment. HS-1371 rescues cells from TNF-induced necroptosis. It rescues cells from RIP3-dependent necroptotic cell death but not apoptotic cell death[1].
Kinase Assay Enzymatic assays
The inhibitory activities of all compounds toward RIP3 were measured by Reaction Biology Corp by means of radiometric kinase assays ([γ-32P]ATP). The enzymatic activity of RIP3 was monitored using 20 μM of myelin basic protein (MBP) dissolved in freshly prepared reaction buffer (20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% BRIJ-35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO). Each putative RIP3 inhibitor was dissolved in 100% DMSO at specific concentrations and serially diluted with epMotion 5070 in DMSO. Human RIP3 and 20 μM of peptide substrate (MBP) were added to the reaction buffer. After delivering the candidate inhibitor dissolved in DMSO to the kinase reaction mixture using Acoustic technology (Echo550; nanoliter range), the reaction mixture was incubated for 20 min at room temperature. To initiate the enzymatic reaction, 33P-ATP with specific activity of 10 μCi/μL was added to the reaction mixture to reach a final ATP concentration of 10 μM. Radioactivity was then monitored using the filter binding method after incubation of the reaction mixture for 2 h at room temperature. At given concentrations of inhibitor, biochemical potency was measured by the percent remaining kinase activity with respect to the vehicle (dimethyl sulfoxide) reaction. Curve fits and IC50 values were then obtained using the PRISM program. The ATP-competitive inhibitor staurosporine (STSP) was employed as a positive control in this study because of its high biochemical potency against various kinases including RIP3.
Cell Research Cell lines HT-29 cells
Concentrations 5 μM
Incubation Time 2 h
Method

HT-29 cells were pretreated with Nec-1 (40 μM), DAB (5 μM) or HS-1371 (5 μM) for 2 h and then treated with TSZ for 4 h. Cell lysates were immunoprecipitated with anti-RIP3 antibody.

Chemical Information & Solubility

Molecular Weight 384.47 Formula

C24H24N4O
CAS No. 2158197-70-5 SDF --
Smiles CC1=CC=C(C=C1)OC2=C3C=CC(=CC3=NC=C2)C4=CN(N=C4)C5CCNCC5
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 13 mg/mL ( (33.81 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 4 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy HS-1371 | HS-1371 supplier | purchase HS-1371 | HS-1371 cost | HS-1371 manufacturer | order HS-1371 | HS-1371 distributor